Kinara https://validator.w3.org/feed/docs/rss2.html CX on the Upswing, Agency Consolidation and So, So Much AI: Life Sciences Leaders Reflect on a Turbulent 2025 Home Articles Durable Innovation: How Incoming Argenx CEO Karen Massey Makes Breakthrough Thinking Repeatable Launch Excellence De-Mythologized: A Q&A with Phathom CEO Steve Basta Durable Innovation: A Q&A with Incoming Argenx CEO Karen Massey The Kinara Innovation Playbook: Phathom Pharmaceuticals and the Imperative to Swim Outside Your Lane The Understated Evolution of the Medical Affairs Function The Kinara Innovation Playbook: AstraZeneca and the Discipline of Commercial Innovation Podcast Lori Englebert, Chief Commercial Officer, Compass Pathways ‘The Most Creative Ideas Come From the Constraint’: Keeping the Spirit of Innovation Alive During Lean Times Launch Excellence De-Mythologized: Phathom CEO Steve Basta on his company’s bold bet on GERD Five Questions Meg Rivera, former SVP, U.S. market president, Organon and CMO, head of commercial, Akili Interactive Zero-Click Engagement: Designing for Invisible Influence in Pharma 9 Healthcare Leaders on the Trends Worth Taking Seriously in 2026 40 Years on the HIV Front Lines with ViiV’s ‘Good Troublemaker’ Kimberly Smith Conviction and Calculation: Collegium’s Vikram Karnani on Why Playing It Safe Is the Biggest Risk Placeholder: Asif Ali/Sanofi Looking Back on Kinara’s 2025 Podcasts and Videos Conviction and Calculation: A Q&A with Collegium CEO Vikram Karnani Gilead’s Ascending CX Leader Silvio Silva Does the PrEP Work – And Much More Happy Birthday to Us: A Look Inside Kinara’s First Year The Conversations We Should Have Had: A Personal and Professional Journey Through Alzheimer’s Disease The Mechanics of Pharma M&A with Devang Bhuva, SVP, Corporate Development at Gilead Sciences Articles Back to the Bubble: The AI Debate Intensifies Navigating the Digital Misinformation Crisis: Where Do We Go From Here? Are We Living Through an AI Bubble? Women’s Health, GLP-1s and ‘AI Everywhere’ Drive the Conversation at HLTH 2025 Health Above All: Eli Lilly’s Jennifer Oleksiw and the CX Revolution Revolutionizing Diagnostics: Exact Sciences CEO on What’s Next Advancing Neurohealth: Alkermes CEO on Innovation and Progress From Doctor to Drug Developer: NewAmsterdam Pharma’s CEO on Transforming Patient Care Job Board Building a First-Tier Pharma Culture: Bruce Cozadd CEO of Jazz Pharmaceuticals Transforming Maternal Mental Health: Sage Therapeutics’ CEO on the Future of Postpartum Depression Treatment Breaking Down Barriers: Akari’s CEO on the Future of Cancer Treatment Science and Service: Ascendis’ Jay Donovan Wu on Leading with Authenticity in the Rare Disease Space ‘Health Above All’: A Q&A With Lilly’s Jennifer Oleksiw ‘Not Playing a Role Isn’t an Option’: Meredith Gannon’s Missions to Transform Marketing and Maternal Care ‘We Sought the Asset Out’: Inside Iterum’s Race to Reshape the UTI Treatment Market Stephanie Loiseau, head of marketing, Sun Pharma Randevyn Piérre, Head of U.S. External Affairs, ViiV Healthcare Same Question, Different Answer: Fixing AI Wobble in Pharma AI Hype, Meet Humanity: Takeaways From Fierce Pharma Week 2025 The Mechanics of Pharma M&A: A Q&A With Gilead’s Devang Bhuva Will McMahon, Director, Omnichannel Strategy, AstraZeneca Geetha Parachuru, Director of Commercial Digital Products, Gilead Sciences